Trial Profile
A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients With Advanced Basal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Silmitasertib (Primary)
- Indications Basal cell cancer; Carcinoma
- Focus Adverse reactions
- Sponsors Senhwa Biosciences
- 27 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 27 Feb 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2023.
- 27 Feb 2023 Status changed from recruiting to active, no longer recruiting.